Gene expression profiles of ERCC1, TYMS, RRM1, TUBB3 and EGFR in tumor tissue from non-small cell lung cancer patients
- Author:
- No author available
- Journal Title:
- Chinese Medical Journal
- Issue:
- 8
- DOI:
- 10.3760/cma.j.issn.0366-6999.20132949
- Key Word:
- ERCC1 gene;TYMS gene;RRM1 gene;TUBB3 gene;EGFR gene;liquidchip;non-small cell lung cancer
Abstract： Background Personalized medicine becomes essential in lung cancer treatment,however lung-cancer-related gene expression profiles in Chinese patients remain unknown.In this study,the correlation of gene expression profiles and clinical characteristics in non-small-cell lung cancer (NSCLC) was investigated.Methods Seventy-six Chinese patients with NSCLC were enrolled in the study to investigate mRNA expression profiles of excision repair cross complement group 1 (ERCC1),thymidylate synthetase (TYMS),ribonucleotide reductase (RRM1),class Ⅲ β-tubulin (TUBB3),and epidermal growth factor receptor (EGFR) genes and their correlation with patient clinical characteristics.A novel liquidchip technology was used to detect mRNA expression levels in formalin fixed paraffin embedded tumor pathology samples.The relationships between gene expression and clinical characteristics were assessed using the Mann-Whitney test.Results ERCC1 mRNA levels were higher in tumors from patients with metastatic disease than patients with nonmetastatic disease (P=0.021),and higher in adenocarcinomas than squamous cell carcinomas (P=0.006).Increased TUBB3 mRNA expression levels were found in patients with performance status (PS) 1 in comparison with PS 0 (P=0.049),with poorly differentiated tumors in comparison with tumors that were moderately and well differentiated (P ≤0.000 1),and with advanced stage in comparison with early stage disease (P≤0.000 1).Conclusions ERCC1 mRNA levels were higher in metastatic adenocarcinoma NSCLC; TUBB3 mRNA levels were significantly higher in poody differentiated tumors and in advanced stage NSCLC,which indicates the poor prognosis.
- [1]REN Guan-jun,ZHAO Yuan-yuan,ZHU Yu-jia,etc.Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer[J].2011,(1).
- [2]Vilmar A,Sorensen JB.Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.[J].2009,64(2).
- [3]Zhang AG,Crawford KL,McMaster GK,etc.A multiplex branched DNA assay for parallel quantitative gene expression profiling[J].2006,352(1).
- [4]Guéna?lle Levallet,Emmanuel Bergot,Martine Antoine,etc.High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non-Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway.[J].2012,11(5).
- [5]D M, Parkin.Global cancer statistics in the year 2000.[J].2001,2(9).
- [6]Haluska FG,Louis DN,Christiani DC,etc.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.[J].2004,350(21).
- [7]Xu J,Wu S,Zhu Z,etc.A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples.[J].2010,48(8).
- [8]Aoe M,Toyooka S,Yoshino T,etc.ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.[J].2008,59(3).
- [9]Cantor A,Sharma S,Kusmartseva I,etc.RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.[J].2006,24(29).
- [10]P G, Johnston,H J, Lenz,C G, Leichman,etc.Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.[J].1995,55.
- [11]Dumontet C,Seve P.Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?[J].2008,9(2).
- [12]Yokouchi H,Asahina H,Yamazaki K,etc.Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.[J].2006,54(3).
- [13]Kim TY,Kim TM,Kang CH,etc.Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.[J].2010,5(3).
- [14]Tonato M,Taron M,Stephens C,etc.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.[J].2003,22(23).
- [15]Sequist LV,Martins RG,Spigel D,etc.First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.[J].2008,26(15).
- [16]Chen T,Sharma A,Haura E,etc.DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.[J].2007,356(8).
- [17]Helfrich BarbaraA,Hirsch FredR,Franklin WilburA,etc.Epidermal growth factor receptor family in lung cancer and premalignancy.[J].2002,29(1 Suppl.4).
- [18]Santoni Rugiu E,Vilmar AC,Sorensen JB.Class III {beta}-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial.[J].2011,17(15).